(Q35038779)

5 August 2017

1 reference

title

Cyclin-dependent kinases as new targets for the prevention and treatment of cancer (English)

1 reference

5 August 2017

Adrian M Senderowicz

1

1 reference

5 August 2017

1 October 2002

1 reference

Hematology / Oncology Clinics of North America

5 August 2017

1 reference

5 August 2017

16

1 reference

5 August 2017

1229-1253

1 reference

5 August 2017

5

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

5 August 2017

1 reference

7 January 2021

The role of RB in cell cycle control

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Role of the retinoblastoma protein in the pathogenesis of human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Cyclin-dependent kinases: engines, clocks, and microprocessors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Human cyclin K, a novel RNA polymerase II-associated cyclin possessing both carboxy-terminal domain kinase and Cdk-activating kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Identification of multiple cyclin subunits of human P-TEFb

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

CDK inhibitors: positive and negative regulators of G1-phase progression

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

New functional activities for the p21 family of CDK inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

The regulation of E2F by pRB-family proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Cell cycle and cancer: critical events at the G1 restriction point.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Multiple molecular levels of cell cycle regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Cyclins and cyclin-dependent kinases: theme and variations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

The retinoblastoma protein and cell cycle control

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Preclinical and clinical development of cyclin-dependent kinase modulators

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

pRb and the cdks in apoptosis and the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Cell cycle control and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

A Restriction Point for Control of Normal Animal Cell Proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Cdk inhibitors in development and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Cell cycle checkpoints: preventing an identity crisis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

When checkpoints fail

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

The retinoblastoma protein pathway and the restriction point

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Small molecule modulators of cyclin-dependent kinases for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Chemical inhibitors of cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Cyclic activation of histone H1 kinase during sea urchin egg mitotic divisions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Characterization of novel inhibitors of cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Distinct roles for cyclin-dependent kinases in cell cycle control

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

G1/S cell cycle blockers and inhibitors of cyclin-dependent kinases suppress camptothecin-induced neuronal apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Cleavage of CDK inhibitor p21(Cip1/Waf1) by caspases is an early event during DNA damage-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extracts

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Preparation and analysis of cDNA from a small number of hematopoietic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Flavopiridol inhibits P-TEFb and blocks HIV-1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

28 Use and specificity of staurosporine, UCN-O1, and calphostin C as protein kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

UCN-01, a selective inhibitor of protein kinase C from Streptomyces.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Molecular determinants of UCN-01-induced growth inhibition in human lung cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Apoptosis and the prognostic significance of p53 mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900049-7

7 January 2021

10.1016/S0889-8588(02)00049-7

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12512390